» Articles » PMID: 35909953

Polymyxin Resistance in Clinical Isolates of in Brazil: Update on Molecular Mechanisms, Clonal Dissemination and Relationship With KPC-Producing Strains

Abstract

In Brazil, the production of KPC-type carbapenemases in Enterobacteriales is endemic, leading to widespread use of polymyxins. In the present study, 502 isolates were evaluated for resistance to polymyxins, their genetic determinants and clonality, in addition to the presence of carbapenem resistance genes and evaluation of antimicrobial resistance. Resistance to colistin (polymyxin E) was evaluated through initial selection on EMB agar containing 4% colistin sulfate, followed by Minimal Inhibitory Concentration (MIC) determination by broth microdilution. The susceptibility to 17 antimicrobials was assessed by disk diffusion. The presence of , and carbapenemases was investigated by phenotypic methods and conventional PCR. Molecular typing was performed by PFGE and MLST. Allelic variants of the gene were screened by PCR and chromosomal mutations in the , , , and genes were investigated by sequencing. Our work showed a colistin resistance frequency of 29.5% (n = 148/502) in isolates. Colistin MICs from 4 to >128 µg/mL were identified (MIC = 64 µg/mL; MIC >128 µg/mL). All isolates were considered MDR, with the lowest resistance rates observed for amikacin (34.4%), and 19.6% of the isolates were resistant to all tested antimicrobials. The gene was identified in 77% of the isolates, in consonance with the high rate of resistance to polymyxins related to its use as a therapeutic alternative. Through -PFGE, 51 pulsotypes were identified. MLST showed 21 STs, with ST437, ST258 and ST11 (CC11) being the most prevalent, and two new STs were determined: ST4868 and ST4869. The gene was identified in 3  isolates. Missense mutations in chromosomal genes were identified, as well as insertion sequences in . Furthermore, the identification of chromosomal mutations in isolates belonging from CC11 ensures its success as a high-risk epidemic clone in Brazil and worldwide.

Citing Articles

Efficacy of colistin-based combinations against pandrug-resistant whole-genome-sequenced Klebsiella pneumoniae isolated from hospitalized patients in Egypt: an in vitro/vivo comparative study.

Attalla E, Khalil A, Zakaria A, Evans R, Tolba N, Mohamed N Gut Pathog. 2024; 16(1):73.

PMID: 39627871 PMC: 11616336. DOI: 10.1186/s13099-024-00667-z.


Prevalence and molecular characterization of carbapenem-resistant Enterobacterales in patients from a public referral hospital in a non-metropolitan region of Brazil during and post the SARS-CoV-2 pandemic.

Fochat R, de Lelis Araujo A, Pereira Junior O, Silverio M, Figueiredo de Castro Nassar A, Junqueira M Braz J Microbiol. 2024; 55(4):3873-3884.

PMID: 39352656 PMC: 11711724. DOI: 10.1007/s42770-024-01531-7.


Evaluating the accuracy of the MBT Lipid Xtract Kit for assessing colistin resistance in comparison to broth microdilution.

Lo C, Ritchie G, Bilawka J, Gowland L, Chorlton S, Jang W J Med Microbiol. 2024; 73(9).

PMID: 39222340 PMC: 11368154. DOI: 10.1099/jmm.0.001881.


Polymyxin resistance in Enterobacter cloacae complex in Brazil: phenotypic and molecular characterization.

Santos da Costa B, Peixoto R, da Conceicao Neto O, da Silva Pontes L, Tavares E Oliveira T, Tavares Teixeira C Braz J Microbiol. 2024; 55(4):3541-3550.

PMID: 39210190 PMC: 11712032. DOI: 10.1007/s42770-024-01464-1.


Adjuvants restore colistin sensitivity in mouse models of highly colistin-resistant isolates, limiting bacterial proliferation and dissemination.

Koller B, Jania L, Li H, Barker W, Melander R, Melander C Antimicrob Agents Chemother. 2024; 68(10):e0067124.

PMID: 39194205 PMC: 11459950. DOI: 10.1128/aac.00671-24.


References
1.
Kitchel B, Rasheed J, Patel J, Srinivasan A, Navon-Venezia S, Carmeli Y . Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009; 53(8):3365-70. PMC: 2715580. DOI: 10.1128/AAC.00126-09. View

2.
Gales A, Jones R, Sader H . Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006; 12(4):315-21. DOI: 10.1111/j.1469-0691.2005.01351.x. View

3.
Poirel L, Naas T, Nordmann P . Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2009; 54(1):24-38. PMC: 2798486. DOI: 10.1128/AAC.01512-08. View

4.
Kazmierczak K, de Jonge B, Stone G, Sahm D . In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018; 73(10):2782-2788. DOI: 10.1093/jac/dky266. View

5.
Rossi F, Girardello R, Cury A, di Gioia T, Nobrega de Almeida Jr J, Duarte A . Emergence of colistin resistance in the largest university hospital complex of São Paulo, Brazil, over five years. Braz J Infect Dis. 2016; 21(1):98-101. PMC: 9425531. DOI: 10.1016/j.bjid.2016.09.011. View